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Background: While it is known that acute respiratory illness (ARI) is caused by an array of viruses, less is known about
co-detections and the resultant comparative symptoms and illness burden. This study examined the co-detections, the
distribution of viruses, symptoms, and illness burden associated with ARI between December 2012 and March 2013.
Methods: Outpatients with ARI were assayed for presence of 18 viruses using multiplex reverse transcriptase
polymerase chain reaction (MRT-PCR) to simultaneously detect multiple viruses.
Results: Among 935 patients, 60% tested positive for a single virus, 9% tested positive for ≥1 virus and 287 (31%)
tested negative. Among children (<18 years), the respective distributions were 63%, 14%, and 23%; whereas for
younger adults (18–49 years), the distributions were 58%, 8%, and 34% and for older adults (≥50 years) the
distributions were 61%, 5%, and 32% (P < 0.001). Co-detections were more common in children than older adults
(P = 0.01), and less frequent in households without children (P = 0.003). Most frequently co-detected viruses were
coronavirus, respiratory syncytial virus, and influenza A virus. Compared with single viral infections, those with
co-detections less frequently reported sore throat (P = 0.01), missed fewer days of school (1.1 vs. 2 days; P = 0.04),
or work (2 vs. 3 days; P = 0.03); other measures of illness severity did not vary.
Conclusions: Among outpatients with ARI, 69% of visits were associated with a viral etiology. Co-detections of specific
clusters of viruses were observed in 9% of ARI cases particularly in children, were less frequent in households without
children, and were less symptomatic (e.g., lower fever) than single infections.
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Each year, hundreds of millions of people are afflicted
with viral respiratory tract infections most commonly
caused by human adenovirus (ADNO), human coronavirus
(CoV), human metapneumovirus (HMPV), human rhino-
virus (HRV), influenza virus (influenza), parainfluenza virus
(PIV), and respiratory syncytial virus (RSV). Moderate to
severe respiratory tract infections may lead patients to seek
outpatient medical attention. Yet, only a portion of these
medically attended acute respiratory infections (ARI) has
been routinely tested to determine their etiology because* Correspondence: tnowalk@pitt.edu
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unless otherwise stated.rapid testing can be expensive and treatment options for
viral infections are limited. New assays using multiplex re-
verse transcriptase polymerase chain reactions (MRT-PCR)
are available allowing for relatively rapid detection of
multiple virus types and simultaneous comparison of pa-
tient characteristics, symptoms, severity of illness and prod-
uctivity across multiple viruses.
During the 2012–2013 influenza season, the multi-center
U.S. Influenza Vaccine Effectiveness (Flu VE) Network,
funded by the Centers for Disease Control and Prevention
(CDC), conducted a study to determine the effectiveness of
the season’s influenza vaccine using singleplex RT-PCR
(SRT-PCR) to detect influenza virus. The University of
Pittsburgh site of the Flu VE Network also used MRT-PCR.ntral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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The purposes of this study were to: 1) examine the dis-
tribution of viruses associated with ARI visits during
December 2012 through March 2013 in Allegheny
County, Pennsylvania, using MRT-PCR; and 2) compare
demographic characteristics, symptoms, and consequences
of various infections and of co-detections vs. single or no
infections. A previous, similar study [1] used the same
methodology to examine ARI in 2011–2012. Because the
onset, severity and length of the influenza season vary year
to year, the present study differs in its epidemiology and its
focus on viral co-detections.Methods
Study design
Participants
Participants provided informed consent and were enrolled
in the University of Pittsburgh’s center for the US Flu VE
Network study described previously [2]. The parent study
used a test negative case control study design [3,4], where
the proportion vaccinated among those who test positive
for influenza is compared with the proportion vaccinated
among those who test negative. Eligibility criteria included
age ≥6 months as of 9/1/2012 and presentation at one of
the participating primary care centers for treatment of an
upper respiratory illness of ≤7 days duration, with cough,
and not taking an influenza antiviral (oseltamivir or zana-
mivir) before the medical visit. Results from influenza
testing were not available soon enough for clinical decision-
making with regard to antiviral prescribing. Antiviral medi-
cation prescribed as a result of the visit did not affect
eligibility. Emergency department visits were not included.
Influenza vaccination status was combined from electronic
medical record (EMR) data and self-report.Specimen collection
All patients except infants (<2 y) were sampled by two
polyester swabs (Remel), one each on the nasal and oro-
pharyngeal mucosa; infants were sampled by nasal swabs
only. The swabs were combined in one cryovial containing
viral transport medium, stored refrigerated, and delivered
to the UPMC Clinical Virology Laboratory within 72 hours.
Specimens were stored in a lysis buffer and aliquotted for
nucleic acid isolation and detection of influenza virus using
CDC’s SRT-PCR test and a MRT-PCR test using the
eSensor XT-8 instrument and respiratory viral panel from
GenMark Diagnostics. All SRT-PCR influenza positive
specimens (n = 335) and a random sample of SRT-PCR in-
fluenza negative specimens (n = 596) were analyzed with
MRT-PCR for a total of 935 of the 1171 specimens from
the parent study. Four additional influenza cases were
identified by MRT-PCR.Nucleic acid extraction and RT-PCR
Isolation of viral nucleic acid from control material and
patient specimens was performed using an EasyMag auto-
mated extractor (bioMerieux, Durham, NC) as previously
described [5]. Previously published, virus-specific primer
and probe nucleotide sequences were used for detection
of influenza A and B virus RNA [5] using the ABI 7500
Real-Time PCR Instrument (Applied Biosystems, Foster
City, CA).
The eSensor RVP MRT-PCR assay (GenMark Diagnos-
tics) is currently approved for clinical use in Europe. It has
the same methodological characteristics but a broader
range of viral analytes than the U.S. FDA-approved
version. This panel includes adenovirus (ADNO) groups
B, C, and E; coronaviruses (CoV) 229E, HKU1, OC43, and
NL63; seasonal influenza A virus (including H1N1 and
H3N2 subtype determination); influenza B virus; hMPV,
PIV types 1, 2, 3, and 4; RSV types A and B; and HRV. The
Genmark assay panel does not include enteroviruses, and
in our laboratory, does not detect several major enterovi-
ruses, i.e., enterovirus 68, enterovirus 71, and Coxsackie
virus A9 (unpublished results).
Nucleic acids were extracted as for the SRT-PCR assay,
with the addition of 10 μl of bacteriophage MS2 internal
control (included in the eSensor RVP kit) to each speci-
men immediately prior to extraction. Specimens were
tested by the eSensor XT-8 instrument according to the
manufacturer's instructions and published protocols [6].
Demographic and other variables
Participants completed surveys at enrollment from which
age, race, personal smoking status and household smoking
(someone in the household smokes), household compos-
ition, asthma diagnosis, exercise, influenza vaccination sta-
tus, symptoms of ARI, self-reported overall health before
ARI, subjective social status using a 10-point scale compar-
ing one’s overall life situation with others, and self-reported
severity of illness on day of enrollment, measured using a
100-point visual analog scale (VAS) were determined. Body
Mass Index (BMI) was calculated from self-reported height
and weight. Severity of illness, time to recovery, and loss of
productivity were assessed on the follow-up survey com-
pleted at least 7 days post enrollment. Study data were
collected and managed using REDCap electronic data cap-
ture tools [7].
Statistical analyses
Similar viruses were combined and only single viruses or
virus groups that were detected in more than 20 samples
were used in the analyses. The final six groups were no
virus detected, HRV, CoV, RSV, influenza virus type B, and
influenza virus type A. Descriptive statistics are presented
as means and standard deviations for continuous variables
and percentages for discrete variables. Participants were
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young adults (18–49 years) and older adults (≥50 years).
Bivariate multinomial regression models assessed the
association of patient characteristics with the MRT-
PCRs. The dependent variable was the virus group and the
independent variables were the participants’ personal char-
acteristics. Logistic regression models assessed the associ-
ation of baseline demographic and clinical characteristics
with virus type (single virus infection vs. co-detection). For
discrete outcome measures with more than two levels,
multinomial logistic regression models were used. One
way analysis of variance was used for continuous out-
comes. For time-to-event outcomes, Kaplan-Meier curves
estimated the cumulative proportion of normal activity.
Log rank tests were used to test for differences in the cu-
mulative proportions among the virus groups. Post-hoc
pairwise comparisons were made with a Bonferroni cor-
rection (p value < 0.05/15 indicating statistical signifi-
cance). Analyses were conducted using SAS version 9.2
(SAS Institute, Inc., Cary NC).
Results
Relationship of viruses to demographic characteristics
and symptoms
Among the 935 ARI patients sampled over the 17-week
study period, all completed the enrollment questionnaire
and 83.3% completed a follow-up survey.
The distributions of viral infections varied by week
(P < 0.001), and are shown in Figure 1. Overall, HRV
peaked in December with a second peak in March; in-
fluenza A peaked in January; CoV and RSV in February;
and influenza B was not evident until late in the season
and peaked in April. The overall cumulative distribution
of return to usual activities was 1.5% by 1 day, 4.6% by
3 days, 10.9% by 5 days, 17% by 6 days, 29.3% by 7 days,
45.1% by 8 days and 100% by 9 days (data not shown).
Table 1 shows the demographic and illness characteris-
tics of patients with five single virus groups and no virusFigure 1 Temporal epidemiology of virus distribution.detected. Hispanic ethnicity, vaccination status, and at-
tendance at school outside the home varied significantly
by virus category. For example, influenza vaccination
was more often reported among those presenting with
CoV, HRV and RSV than among those with either influ-
enza A or B; 42% of those <18 years old with influenza
A or B attended school outside the home compared with
26.3% of those with no virus detected. Fever and fatigue
were more prominent with influenza detection and
wheezing was less common with CoV. Use of influenza
antiviral medicines varied significantly by virus category;
59% of those with influenza A or B were prescribed an
antiviral medication compared with 14.8% of those with
other viral infections or 26.2% of those with no viral in-
fection. Temperature at enrollment was higher among
those with influenza than those with ARI of other eti-
ology, and baseline severity of illness was greater (lower
score) among those with influenza. Days from onset to
enrollment (seeking outpatient medical treatment) were
greater among those with ARI with no virus detected
than those with a viral infection.
Table 2 shows the outcomes for patients in the five
single virus groups and those with no virus detected.
Hours of work missed due to ARI varied significantly by
virus group, appearing worse for influenza A and B. Self-
reported time to return to normal activity varied by virus
group (P = 0.02) and is depicted in Figure 2.
Distribution of viruses and co-detections
Table 3 shows the distribution of single virus infections and
co-detections, with the numbers for co-detections repre-
senting viruses detected, not numbers of patients. Single
virus infections were detected among 563 (60.2%) patients,
co-detections were found among 85 (9.1%) patients and
287 (30.7%) were negative for all tested viruses. The viruses
most frequently co-detected were CoV (49 times), RSV (39
times), and influenza A (39 times). The distributions varied
by age. For children, the percentages of single virus, mul-
tiple viruses, and no virus detected were 63%, 14%, and
23%, respectively; whereas for young adults, the percentages
were 58%, 8%, and 34% and for older adults the percentages
were 61%, 5%, and 32%, respectively (P < 0.001 for overall
distributions; data not shown).
Compared with single infections, co-detections were
more common in children than older adults (Table 4) and
less frequent in households without children. Co-detections
were less common if sore throat was present, but did not
vary by other symptoms. Average body mass index was
below normal among those with co-detections and more
likely to be low among this group compared with those
with single infections.
Ability to perform usual activities, return to normal
activities, household members having to miss work, sleep
quality, productivity, severity of illness, hours of work
Table 1 Demographics and clinical characteristics by virus type in 2012-2013
Virus type
All (N = 819)a CoV (N = 111) HRV (N = 48) Influenza A, H3 (N = 211) Influenza B (N = 60) RSV (N = 102) No Virus (N = 287) p value
Variable N n % n % n % n % n % n %
Baseline Demographics and Health
Characteristics (categorical responses)
Race 0.32
White 703 94 13.4 40 5.7 191 27.2 51 7.2 89 12.7 238 33.8
Black 71 11 15.5 5 7 10 14.1 3 4.2 7 9.9 35 49.3
Other 37 5 13.5 3 8.1 9 24.3 3 8.1 6 16.2 11 29.7
Sex 0.14
Male 304 33 10.9 21 6.9 90 29.6 24 7.9 40 13.1 96 31.6
Female 514 78 15.2 27 5.2 121 23.5 36 7 62 12.1 190 37.0
Hispanic 0.001
No 799 110 13.8 48 6 209 26.2 52 6.5 101 13 278 34.9
Yes 17 1 5.9 0 0 2 11.8 8 47 1 5.9 5 29.4
Age group 0.10
6 mos. – 17 years 222 32 14.4 14 6.3 59 26.6 16 7.2 38 17.1 63 28.4
18 – 49 years 346 54 15.6 19 5.5 86 24.8 26 7.5 30 8.7 131 37.9
≥50 years 250 25 10 15 6 66 26.4 18 7.2 34 13.6 92 36.8
Household members ≥ 18 0.41
1 154 26 16.9 8 5.2 35 22.7 7 4.6 17 11 61 39.6
2 454 58 12.8 30 6.6 117 25.8 36 7.9 65 14.3 148 32.6
≥3 210 27 12.8 10 4.8 59 28.1 17 8.1 20 9.5 77 36.7
Household members < 18 0.26
0 369 51 13.8 21 5.7 102 27.6 23 6.2 43 11.7 129 35.0
1 167 21 12.6 10 6 36 21.5 9 5.4 29 17.4 62 37.1
2 166 17 10.2 13 7.8 45 27.1 15 9 20 12.1 56 33.7
≥3 115 22 19.1 4 3.5 28 24.4 13 11.3 10 8.7 38 33.0
Social status 0.26
1-4 103 15 14.6 5 4.8 28 27.2 7 6.8 10 9.7 38 36.9
5 150 24 16 7 4.7 30 20 11 7.3 12 8 66 44.0
6 122 16 13.1 13 10.7 31 25.4 7 5.7 17 13.9 38 31.2
7 - 9 218 24 11 8 3.7 63 28.9 18 8.2 24 11 81 37.2
Smoking status 0.11
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Table 1 Demographics and clinical characteristics by virus type in 2012-2013 (Continued)
Smoker 108 18 16.7 7 6.5 27 25 6 5.5 4 3.7 46 42.6
Non-smoker 488 61 12.5 27 5.5 125 25.6 38 7.8 60 12 177 36.3
Household smoking 0.18
Yes 167 20 12 10 6 42 25.1 7 4.2 17 10.2 71 42.5
No 649 91 14 38 5.9 167 25.7 53 8.2 85 13.1 215 33.1
Asthma status 0.26
Yes 183 18 9.8 13 7.1 45 24.6 15 8.2 18 9.8 74 40.5
No 630 92 14.6 35 5.5 164 26 44 7 83 13.2 212 33.7
Influenza vaccination status 0.05
Yes 403 59 14.6 30 7.4 88 21.9 27 6.7 56 13.9 143 35.5
No 409 51 12.5 18 4.4 121 29.6 33 8.1 44 10.7 142 34.7
Self-reported health status 0.32
Fair/poor 49 6 12.2 3 6.1 9 18.4 1 2.1 5 10.2 25 51.0
Good 226 31 13.7 10 4.4 55 24.4 19 8.4 26 11.5 85 37.6
Very Good 323 45 13.9 19 5.9 86 26.6 31 9.6 42 13 100 31.0
Excellent 219 29 13.2 16 7.3 61 27.9 9 4.1 28 12.8 76 34.7
Current employment (age ≥18 years) 0.18
No 145 18 12.4 7 4.8 34 23.4 7 4.8 22 15.2 57 39.3
Yes 351 48 13.7 23 6.6 97 27.6 31 8.8 32 9.1 120 34.2
Attends school outside home
(age <18 years)
0.02
No 34 6 17.6 4 11.7 4 11.7 1 2.9 11 32.3 8 23.5
Yes 148 18 12.2 9 6.1 49 33.1 13 8.8 20 13.5 39 26.3
Symptoms of ARI and Antiviral Use
(categorical responses)
Fever <.001
Yes 479 61 12.7 19 4** 164 34.2* 45 9.4 53 11.1‡ 137 28.6
No 339 50 14.7 29 8.5 47 13.9 15 4.4 49 4.5 149 44
Fatigue <.001
Yes 634 87 13.7 30 4.7** 182 28.7 54 8.5 74 11.7 207 32.7
No 184 24 13 18 9.8 29 15.8 6 3.3 28 15.2 79 42.9
Wheezing 0.01
Yes 297 25 8.4 18 6.1 89 30* 23 7.7 45 15.1 97 32.7
No 521 86 16.5 30 5.8 122 23.4 37 7.1 57 10.9 189 36.3
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Table 1 Demographics and clinical characteristics by virus type in 2012-2013 (Continued)
Sore throat 0.11
Yes 589 84 14.3 37 6.3 164 27.8 39 6.6 71 12.1 194 32.9
No 229 27 11.8 11 4.8 47 20.5 21 9.2 31 13.5 92 40.2
Nasal congestion 0.12
Yes 711 101 14.2 45 6.3 183 25.7 51 7.2 93 13.1 238 33.5
No 107 10 9.4 3 2.8 28 26.2 9 8.4 9 8.4 48 44.8
Shortness of breath 0.52
Yes 352 49 13.9 19 5.4 90 25.6 33 9.4 43 12.2 118 33.5
No 466 62 13.3 29 6.2 121 26 27 5.8 59 12.7 168 36
Antiviral medication prescribed, (not including HRV) †
0.002
No 564 83 14.7 - - 151 26.8 47 8.3 80 14.2 203 36
Yes 61 5 8.2 - - 31 50.8 5 8.2 4 6.6 16 26.2
Baseline Demographics and Symptoms (continuous variables)
Variable N n Mean (SD) n Mean (SD) n Mean (SD) n Mean (SD) n Mean (SD) n Mean (SD) p value
Age 818 111 33.8 (21.4) 48 32.8 (21.2) 211 36.2 (22.3) 60 34.9 (20.6) 102 34.7 (20.6) 286 37.2 (21.3) 0.65
BMI 817 110 20.5 (14.2) 48 20.6 (14.0) 211 21 (14.3) 60 21.7 (13.9) 102 18.7 (15.2) 286 22.9 (13.4) 0.16
Temperature 559 72 98.7 (1.10) 26 98.6 (0.80) 161 99.6 (1.50) 44 99.8 (1.50) 62 98.9 (1.20) 194 98.9 (1.20) <0.001
Days from onset to enrollment 818 111 3.23 (1.46) 48 3.35 (1.45) 211 2.82 (1.40) 60 3.38 (1.22) 102 3.55 (1.35) 286 3.71 (1.48) <0.001
Severity of illness at enrollment
(VAS), range = 1 - 100
818 111 62.2 (18.2) 48 64.9 (21.2) 211 55.7 (17.7) 60 56.3 (20.5) 102 61.3 (17.4) 286 61.3 (19.2) 0.002
aN reflects the total number of participants, reduced by the number of co-detections and viruses with <20 detections.
*Significantly different from CoV in post-hoc comparisons P ≤ 0.001; post-hoc comparisons are based on a Bonferroni correction for multiple comparison (P < .003).
**Significantly different from Influenza A and B in post hoc comparisons, P ≤ 0.001.
‡Significantly different from Influenza A in post hoc comparisons, P ≤ 0.001
†Antiviral medication was never prescribed for those with HRV, leading to cells with zeroes in them.
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Table 2 Outcomes of patients presenting with medically attended acute respiratory infections by viral etiology in 2012-2013
Virus type
Outcomes (categorical variables) All (N = 684)a CoV (91) HRV (43) Influenza A, H3 (185) Influenza B (52) RSV (86) No Virus (227) p value
Variable N n % n % n % n % n % n %
Follow-up survey returned relative
to enrollment date
<0.001
0 – 13 days 394 36 9.1 23 5.8 133 33.8 44 11.2 49 12.4 109 27.7
≥14 days 288 55 19.1 20 6.9 51 17.7 8 2.8 37 12.9 117 40.6
Ability to perform usual activity, range =
(not at all) – 9 (able to perform)
0.08
Not at all (0 – 5) 74 9 10 4 9.5 18 9.7 8 15.4 11 12.9 24 10.8
Somewhat (6 – 8) 232 23 25.6 15 35.7 80 43.3 22 42.3 26 30.6 66 29.6
Able to perform (9) 371 58 64.4 23 54.8 87 47 22 42.3 48 56.5 133 59.6
Household member missed work because
of patient’s illness
0.40
No 563 74 81.3 38 88.4 149 80.5 40 76.9 68 79.1 194 85.8
Yes 120 17 18.7 5 11.6 36 19.5 12 23.1 18 20.9 32 14.2
Sleep quality, range = 0 (worst) – 9 (normal) 0.67
Worst (0 – 4) 52 8 9 4 9.5 10 5.4 2 3.8 9 10.6 19 8.5
Mild (5 – 6) 101 15 16.8 6 14.3 26 14 7 13.5 11 12.9 36 16.1
Moderate (7 – 8) 242 36 40.5 11 26.2 68 36.8 23 44.2 34 40 70 31.4
Normal (9) 280 30 33.7 21 50 81 43.8 20 38.5 31 36.5 98 44
Effect on productivity, range = 0 (no effect
on my work) – 10 (completely prevented
me from working for those age ≥18 years)
0.62
0 – 3 77 15 31.3 5 21.7 17 17.5 4 12.9 7 21.9 29 24.4
4 – 7 153 16 33.3 10 43.5 41 42.3 16 51.6 15 46.9 55 46.2
8 – 10 120 17 35.4 8 34.8 39 40.2 11 35.5 10 31.2 35 29.4
Outcomes (continuous variables)
Variable N n Mean (SD) n Mean (SD) n Mean (SD) n Mean (SD) n Mean (SD) n Mean (SD) p value
For participants <18 years:
Missed school days 147 18 2.4 9 2.1 49 2.9 13 2.9 20 1.8 38 2.5 0.47
(1.9) (2.0) (2.4) (1.9) (1.3) (2.1)
Household member missed work days 118 16 2 5 3 35 3 12 2 18 2 32 2 0.19
(1.1) (2.0) (2.9) (1.9) (1.8) (1.3)
Severity of illness at follow-up (VAS),
range = 1-100
658 86 83 (15.1) 42 83 (16.0) 181 83 (14.4) 50 82 (13.0) 81 83 (14.7) 218 84 (15.7) 0.98
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Table 2 Outcomes of patients presenting with medically attended acute respiratory infections by viral etiology in 2012-2013 (Continued)
For participants ≥18 years:
Number of hours of work missed due to ARI 351 48 14 (12.5) 23 16 (18.0) 97 22 (16.4) 31 22 (17.9) 32 11 (11.5) 120 12 (13.1) 0.001
Multinomial Modeling: Odds Ratios for
derived variables
CoV (n = 91) HRV (n = 43) Influenza A, H3 (n = 185) Influenza B (n = 52) RSV (n = 86) No Virus (n = 227)
OR OR OR OR OR OR p value
Variable (95% CI) (95% CI) (95% CI) (95% CI) (95% CI) (95% CI)
Ability to perform usual activities 0.08
Not at all (0–5) vs. Able to perform (9) 0.74 0.83 0.99 1.74 1.10 Referent
(0.39-1.41) (0.33-2.08) (0.59-1.65) (0.84-3.58) (0.59-2.02)
Somewhat able (6–8) vs. Able to perform (9) 0.63 1.03 1.45 1.58 0.86 Referent
(0.4-0.98) (0.59-1.82) (1.06-2.00) (0.94-2.66) (0.55-1.33)
Household member missed work (days) 1.39 0.80 1.47 1.82 1.61 Referent 0.40
(0.73-2.66) (0.29-2.18) (0.87-2.47) (0.86-3.83) (0.85-3.04)
Sleep Quality 0 (worst quality, unable to sleep) – 9
(pre-illness quality sleep)
0.68
Worst vs. Normal 1.47 1.05 0.68 0.55 1.60 Referent
(0.70-3.08) (0.41-2.72) (0.35-1.31) (0.16-1.92) (0.79-3.27)
Mild vs. Normal 1.40 0.80 0.90 0.98 0.99 Referent
(0.79-2.49) (0.36-1.76) (0.57-1.41) (0.46-2.08) (0.53-1.86)
Moderate vs. Normal 1.36 0.59 0.95 1.30 1.24 Referent
(0.87-2.12) (0.32-1.11) (0.68-1.33) (0.76-2.22) (0.79-1.94)
Effect on productivity 0.64
Worst vs. No effect 0.69 0.97 1.40 1.67 0.87 Referent
(0.35-1.35) (0.37-2.59) (0.78-2.51) (0.62-4.55) (0.37-2.06)
Moderate vs. No effect 0.51 0.96 1.15 1.91 1.02 Referent
(0.26-1.00) (0.37-2.45) (0.65-2.05) (0.73-4.98) (0.46-2.30)
Multinomial Modeling: Hazards Ratio HR HR HR HR HR HR p value
Variable (95% CI) (95% CI) (95% CI) (95% CI) (95% CI) (95% CI)
Time to return to normal activity (days) 0.74 1.06 1.65 1.48 1.22 Referent 0.02
(0.45-1.22) (0.53-2.09) (1.13-2.39) (0.89-2.46) (0.73-2.05)
OR= Odds Ratio; CI = Confidence Interval; SD = Standard Deviation; HR = Hazards ratio.
aN reflects the total number of participants, reduced by the number of co-detections, viruses with <20 detections, and participants without follow-up surveys.
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Table 3 Distribution of Viruses from multiplex viral panel
Among 935 outpatients with medically attended acute
respiratory infections in 2012–13
Virus All samples (N = 935) tested
by multiplex RT-PCR,* n (%)
Singly occurring viruses by type
Coronaviruses (CVOC43, n = 72;
CVNL63, n = 33; CV229E, n = 4;
CVKHU1, n = 2)
111 (11.9)
HRV 48 (5.1)
Influenza type A 213 (22.8)
Influenza type B 60 (6.4)
RSV (A, n = 85 and B, n = 17) 102 (10.9)
Other single viruses (ADNOE,
n = 1; HMPV, n = 8; PIV1,
n = 2; PIV2, n = 9; PIV3, n = 8;
PIV4, n = 1)
29 (3.1)
Single viruses total 563 (60.2)
Co-detections 85 (9.1)
No viruses 287 (30.7)
Co-detected viruses
Virus Co-detected viruses n†
ADNO Dual – CoV, HRV, RSV, Influenza B 5
Triple – CoV/Influenza A, HMPV/RSV 2
CoV Dual – ADNO, CoV, HRV, Influenza B,
HMPV, PIV, RSV
45
Triple – Influenza A/HRV, Influenza
A/ADNO, HRV/RSV
4
HMPV Dual - CoV, Influenza A, RSV 4
Triple – RSV/ADNO 1
HRV Dual – ADNO, CoV, Influenza B, RSV 10
Triple – Influenza A/CoV, RSV/CoV 3
Influenza A Dual – CoV, HRV, HMPV, RSV, PIV 36
Triple – ADNO/CoV, HRV/CoV 2
Influenza B Dual – CoV, ADNO, HRV, Influenza A 9
PIV Dual – CoV, RSV, Influenza A 6
RSV Dual – ADNO, CoV, HRV, Influenza
A, HMPV, PIV
36
Triple – HRV/CoV, HMPV/ADNO 3
*MRT-PCR =multiplex reverse transcriptase polymerase chain
reaction; ADNO = Adenovirus.
CoV = Coronavirus; HMPV = Human Metapneumovirus;
HRV = Human Rhinovirus.
RSV = Respiratory Syncytial Virus; one dual H1N1/H3N2 detection occurred.
†Represents occurrences of viruses, not individual participants.
Figure 2 Testing homogeneity of survival curves for time to
return to normal activity over virus groups.
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differ between those with single infections and those with
co-detected viruses (Table 5). However, those <18 years of
age with co-detections missed fewer days of school (2 vs.
1.1, P = 0.04) and all with co-detections reported fewer
days of work missed by household members to care for
the ill patient (3 vs. 2, P = 0.03).
Discussion
This study, similar to a study conducted in a previous
influenza season [1], examined the distribution of 18 vi-
ruses among individuals seeking outpatient care for ARI
characterized by presence of cough. The 2012–2013 in-
fluenza season was markedly different from the previous
one. Although both seasons were characterized by a pre-
ponderance of influenza A/H1N1pdm09, in 2011–2012,
influenza viruses began circulating in this region at low
levels in December, but did not peak until the spring of
2012, with few influenza B virus detections. Whereas, in
2012–2013, influenza A began circulating in December,
began to wane in late February as a smaller wave of in-
fluenza B began appearing in late February and early
March. Concurrently, HRV peaked in December and in
March, earlier than the previous year when it peaked in
April; CoV was active from late December through March
and RSV was active in February.
Significant differences between viral infections and
symptom variables were observed with fever and fatigue
being more prominent with influenza and wheezing less
common with CoV. Such findings are consistent with the
literature showing that fever is a common symptom for
both HMPV and influenza [8]. Enrollees with influenza
seem to have been sicker, as they more frequently reported
fever, feeling worse at baseline, seeking treatment sooner
and, among adults, missing more work time.
We found that co-detections occurred in 9% of ARI cases.
CoV, RSV and influenza A were the most common co-
detections, whereas, in the previous year, co-detections weremost frequently caused by CoV, HRV and influenza A [1]
and in a longer, year round study, HRV was the most fre-
quent co-infecting virus [9]. We also observed some triple
co-detections involving ADNO, CoV, HMPV, RSV, influenza
A, and HRV. Importantly, we found that co-detections were
more common in children, and were less frequent in
households without children. The association of virus
Table 4 Baseline comparisons using unadjusted odds ratios, between single viral infections (n = 563) and co-detections
(n = 85) in 2012-2013
Variable Single infection % Co-detection % Unadjusted OR (95% CI) P-value
Categorical variables
Race 0.180
White 87.7 12.3 0.61 (0.24-1.53)
Black 79.6 20.4 1.11 (0.36-3.43)
Other 81.2 18.8 Referent
Sex 0.780
Male 87.3 12.7 Referent
Female 86.6 13.4 1.07 (0.67-1.71)
Hispanic 0.940
No 86.9 13.1 Referent
Yes 87.5 12.5 0.95 (0.21-4.23)
Age group 0.010
6 mo-17 years 81.6 18.4 2.51 (1.33-4.72)
18-49 years 87.8 12.2 1.55 (0.81-2.96)
≥50 years 91.8 8.2 Referent
Household members ≥18 0.690
1 89.2 10.8 0.82 (0.39-1.74)
2 86.1 13.9 1.09 (0.63-1.88)
≥3 87.1 12.9 Referent
Household member <18 0.003
0 92.0 8.0 0.45 (0.23-0.90)
1 86.6 13.4 0.80 (0.38-1.68)
2 79.4 20.6 1.34 (0.69-2.62)
≥3 83.8 16.2 Referent
Subjective social status, range = 0-9 0.910
1-4 87.2 12.8 1.25 (0.55-2.88)
5 90.5 9.5 0.89 (0.38-2.09)
6 89.8 10.2 0.97 (0.43-2.21)
≥7 89.5 10.5 Referent
Smoking status 0.260
Smoker 85.9 14.1 1.52 (0.73-3.13)
Non-smoker 90.2 9.8 Referent
Household smoking 0.910
Yes 86.7 13.3 1.03 (0.58-1.86)
No 87.1 12.9 Referent
Asthma Status 0.600
Yes 85.4 14.6 1.16 (0.67-1.99)
No 87.1 12.9 Referent
Influenza vaccination status 0.220
Yes 88.5 11.5 Referent
No 85.1 14.9 1.34 (0.84-2.12)
Self-reported health status 0.090
Fair/Poor 89.7 10.3 0.54 (0.15-1.87)
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Table 4 Baseline comparisons using unadjusted odds ratios, between single viral infections (n = 563) and co-detections
(n = 85) in 2012-2013 (Continued)
Good 86.0 14.0 0.76 (0.43-1.34)
Very good 90.4 9.6 0.49 (0.28-0.86)
Excellent 82.3 17.7 Referent
Ability to perform usual activities 0.190
Not at all (0–5) 84.8 15.2 2.21 (0.85-5.81)
Somewhat (6–8) 87.9 12.1 1.71 (0.64-4.57)
Able to perform (9) 92.5 7.5 Referent
Current employment 0.170
Yes 89.0 11.0 Referent
No 93.8 6.2 0.53 (0.21-1.32)
Child attends school outside home (for those <18 years old) 0.090
Yes 85.1 14.9 Referent
No 73.8 26.2 2.02 (0.88-4.67)
Anti-viral medication prescribed 0.840
Yes 86.8 13.2 Referent
No 87.7 12.3 0.92 (0.40-2.13)
Fever 0.660
Yes 86.4 13.6 1.11 (0.69-1.80)
No 87.7 12.3 Referent
Fatigue 0.370
Yes 87.5 12.5 0.78 (0.46-1.33)
No 84.5 15.5 Referent
Wheezing 0.350
Yes 85.3 14.7 1.24 (0.78-1.98)
No 87.8 12.2 Referent
Sore throat 0.010
Yes 89.2 10.8 0.51 (0.32-0.82)
No 81.0 19.0 Referent
Nasal congestion 0.640
Yes 87.1 12.9 0.85 (0.43-1.68)
No 85.1 14.9 Referent
Shortness of breath 0.600
Yes 87.7 12.3 0.88 (0.56-1.40)
No 86.3 13.7 Referent
Continuous variables
Age, years (units = 5) 34.6 (22.8) 26.3 (20.9) 0.92 (0.87-0.97) 0.002
BMI (units = 2) 20.2 (14.4) 15.3 (14.5) 0.95 (0.92-0.98) 0.004
Temperature (°F) 99.2 (1.4) 99.3 (1.1) 1.03 (0.85-1.26) 0.740
Severity of illness at enrollment (VAS), range = 1–100 (units = 5) 59.2 (18.6) 56.7 (19.1) 0.96 (0.91-1.02) 0.240
Number of days between onset and enrollment 3.2 (1.4) 3.3 (1.3) 1.05 (0.90-1.24) 0.520
Number of days between enrollment and return of follow-up survey
(units = 5)
14.8 (10.9) 15.9 (10.6) 1.04 (0.94-1.16) 0.440
Zimmerman et al. BMC Infectious Diseases  (2015) 15:87 Page 11 of 13
Table 5 Follow-up comparisons between single viral infections (n = 483) and co-detections (n = 68), 2012-2013
Virus type
Single infection Co-detection Unadjusted P value
N = 483 N = 68 OR (95% CI)
Variable % %
Ability to perform usual activities 0.450
Not at all (0–5) 10.8 6.0 0.74 (0.43-1.26)
Somewhat (6–8) 36.1 40.3 1.05 (0.80-1.37)
Able to perform (9) 53.1 53.7 Referent
Return to normal activity 0.570
Not yet return to normal activity 40.6 47.4 1.32 (0.50-3.46)
Never stopped normal activities 59.4 52.6 Referent
Household member missed work 0.100
No 80.7 72.1 Referent
Yes 19.3 27.9 1.63 (0.91-2.89)
Sleep quality, range = 0-9 0.470
Worst (0–4) 7.1 7.5 0.97 (0.59-1.61)
Mild (5–6) 13.6 17.9 1.09 (0.76-1.56)
Moderate (7–8) 37.8 28.4 0.82 (0.61-1.11)
Normal (9) 41.5 46.2 Referent
Effect on productivity (age ≥18 years) 0.130
No effect (0–3) 20.2 13.8 Referent
Moderate (4–7) 43.8 31.0 1.02 (0.84-2.67)
Worst (8–10) 36.0 55.2 1.50 (0.55-1.88)
Mean (SD) Mean (SD) P value
Missed school days due to ARI 2.0 (2.1) 1.1 (1.3) 0.040
Missed work days of household member 3.0 (2.2) 2.0 (0.9) 0.030
Severity of illness at follow-up (VAS), range = 1-100 83.0 (14.6) 86.0 (15) 0.140
Hours of work missed due to ARI among ≥18 years-old 18.0 (15.8) 18.0 (12.1) 0.930
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hanced susceptibility of children to these single
infections.
The clinical impact of co-detections is debatable. In
the literature, dual infections have been linked to more
severe clinical outcomes compared with single virus
infections. These studies have included primarily chil-
dren <5 years, and adults with co-morbidities [10], and
children presenting to emergency departments [11], or re-
sulted from multiple influenza virus infections [12]. How-
ever, in our population of adults and children, we found
that co-detections were significantly less common if sore
throat was present and did not vary by other symptoms.
Moreover, compared with individuals with single viral in-
fections, those with co-detections missed significantly
fewer days of school (1.1 vs. 2 days) or work (2 vs. 3 days).
A recent study of children attending day care in which no
demographic or household variables were related to
co-infections, found that fever was less likely with co-infections [13]. Hence, some data emerging from our study
and others using newly available, highly sensitive and spe-
cific assays for multiple virus infections have not found a
relationship with more severe illness whereas others have.
Indeed, our data suggest that multiple respiratory virus in-
fections are associated with less severe clinical symptoms
particularly fever, and are less detrimental to the patients’
quality of life. The co-detections may represent a com-
mensal situation in which the second virus has no effect
on the predominant infection but is found with these sen-
sitive tests. The contrast in results between studies on
co-detections finding a less versus more severe clinical
course may be related to population, test characteristics,
time of year, and duration of testing period. Further stud-
ies are needed to define underlying viral and host immune
mechanisms and outcomes of multiple respiratory virus
infections.
The sensitivity and specificity of the MRT-PCR com-
pared with SRT-PCR were similar for both years. The
Zimmerman et al. BMC Infectious Diseases  (2015) 15:87 Page 13 of 13sensitivity was 91.1% and specificity was 98.2% in
2011–2012 [1] and the sensitivity was 96% and specifi-
city was 99.8% for influenza A in 2012–2013 [14]. In
2012–13, most of the discordant results were weak pos-
itives on SRT-PCR and the discordant results included
five specimens in which the MRT-PCR was positive for
another virus.
Strengths and limitations
This study offers data on viral infections associated with out-
patient ARI in the US during the winter influenza season,
detected using the eSensor 18 virus panel currently available
in Europe. This panel of viruses includes four CoVs and four
PIVs that are not part of the currently (2015) FDA-cleared
format. Study limitations include the inability to test an in-
clusive sample of all of the ARI specimens with the MRT-
PCR and the fact that health-seeking behavior during illness
is associated with a history of influenza vaccination. The
sample size of detected viruses other than influenza, HRV,
RSV and coronaviruses were too small for sub-analyses.
However, the sample size overall was sufficient to allow
confidence in the relationships between characteristics of
ARI cases and the viruses associated with them during this
time period. Additionally, the viral panel does not contain
bacteria, mycoplasma, and all possible respiratory viruses.
Sampling took place during the influenza season and may
have missed peak seasons for other virus circulation. The
study is strengthened by the similarity of methods used in
a previous influenza season and allows for comparison
of viral activity in two seasons with different influenza
epidemiology.
Conclusions
In this study using multiplex RT-PCR, 69% of outpatient
medically attended ARI during the 2012–2013 influenza
season were associated with a viral etiology. The timing
and distribution of viral infections differed from a previ-
ous influenza season. Co-infections were infrequent but
varied by demographic and household characteristics.
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